Arrowhead Pharmaceuticals (ARWR) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Arrowhead Pharmaceuticals (ARWR) right now is REDEMPLO (plozasiran) launch and label expansion: Plozasiran is now approved for FCS in the U.S., China, Canada, Australia, and the EU, giving Arrowhead its first commercial product. Revenue (FY2025, ended Sept 2025) is ~$829M. If that keeps playing out, the setup is favourable; the risk to it is arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. No one can predict where ARWR trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Arrowhead Pharmaceuticals (ARWR) higher?
1. REDEMPLO (plozasiran) launch and label expansion
Plozasiran is now approved for FCS in the U.S., China, Canada, Australia, and the EU, giving Arrowhead its first commercial product. The larger commercial opportunity would come from broader indications like severe hypertriglyceridemia, where the addressable patient population is far bigger than the rare FCS setting.
2. Partnership economics
The Sarepta collaboration delivered roughly ~$825M in upfront value and has generated additional milestone payments (including ~$100M and ~$200M tranches reported in late 2025). Amgen's olpasiran and other partnered programs add royalty and milestone potential without Arrowhead bearing all the development cost, though the timing of these payments is uneven.
3. Broad RNAi pipeline beyond the liver
Arrowhead's TRiM platform extends siRNA delivery beyond hepatic targets toward lung, muscle, and CNS tissues, supporting candidates in cardiometabolic disease, obesity (such as ARO-INHBE), and pulmonary conditions. A deep, diversified pipeline gives multiple shots on goal but also spreads capital and clinical risk across many programs.
4. Strong balance sheet and runway
Following partner payments and equity offerings, Arrowhead reported total cash resources of roughly ~$1.78B in early 2026. That funding reduces near-term dilution pressure and lets the company advance late-stage trials and the REDEMPLO commercial build-out without immediate financing risk.
What could weigh on ARWR?
Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. The commercial uptake of REDEMPLO in the small FCS population is unproven, and broader label expansion depends on clinical and regulatory outcomes that can fail or slip. Competition in RNAi and lipid-lowering is intense from larger, better-capitalized rivals. Clinical trial setbacks, safety findings, regulatory delays, and partner decisions (including a partner pausing or returning a program) could all materially affect the stock, which is volatile like most clinical-stage biotech.
Where ARWR trades today
A forecast starts from where the stock actually is. These are ARWR's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ARWR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ARWR forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ARWR guide and whether ARWR is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ARWR outlook
The bottom line: what is driving Arrowhead Pharmaceuticals (ARWR) is REDEMPLO (plozasiran) launch and label expansion, with revenue (fy2025, ended sept 2025) at ~$829M. If that keeps playing out the setup is favourable; the risk is arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. No one can predict the price, so treat any ARWR forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ARWR with Walnut
Use Arrowhead Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Arrowhead Pharmaceuticals (ARWR)?
+
No one can reliably predict where ARWR will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Arrowhead Pharmaceuticals higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ARWR higher?
+
The main growth drivers are REDEMPLO (plozasiran) launch and label expansion; Partnership economics; Broad RNAi pipeline beyond the liver. Whether they play out is the real question, not a guaranteed path.
What are the risks to ARWR?
+
Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. The commercial uptake of REDEMPLO in the small FCS population is unproven, and broader label expansion depends on clinical and regulatory outcomes that can fail or slip. Competition in RNAi and lipid-lowering is intense from larger, better-capitalized rivals. Clinical trial setbacks, safety findings, regulatory delays, and partner decisions (including a partner pausing or returning a program) could all materially affect the stock, which is volatile like most clinical-stage biotech.
Will ARWR stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Arrowhead Pharmaceuticals's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ARWR a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ARWR "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.